MARKER THERAPEUTICS, INC.: 10-Q filed 2017-11-14

Name: MARKER THERAPEUTICS, INC.: 10-Q filed 2017-11-14
Creator: MARKER THERAPEUTICS, INC.

What MARKER THERAPEUTICS, INC. reported in its quarterly report filed 2017-11-14 (fiscal Q3 2017): 21 published measures, 62 facts as tagged in accession 0001144204-17-058991.

This filing

Form: 10-Q (quarterly report)
Filed: 2017-11-14
Fiscal period: fiscal Q3 2017
Accession: 0001144204-17-058991 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MARKER THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-09-30	7,704,265	USD
At 2016-12-31	7,921,392	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-09-30	1,768,062	USD
At 2016-12-31	1,736,805	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2017-09-30	5,936,203	USD
At 2016-12-31	6,184,587	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-3,985,510	USD	92
2017-01-01 to 2017-09-30	-8,298,772	USD	273
2016-07-01 to 2016-09-30	-2,102,962	USD	92
2016-01-01 to 2016-09-30	-878,561	USD	274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	-5,960,981	USD	273
2016-01-01 to 2016-09-30	-4,756,266	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	5,717,473	USD	273
2016-01-01 to 2016-09-30	7,766,475	USD	274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-09-30	-154,736,622	USD
At 2016-12-31	-145,815,808	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	10,219,138	shares	92
2017-01-01 to 2017-09-30	9,081,678	shares	273
2016-07-01 to 2016-09-30	7,281,000	shares	92
2016-01-01 to 2016-09-30	6,370,000	shares	274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	10,219,138	shares	92
2017-01-01 to 2017-09-30	9,081,678	shares	273
2016-07-01 to 2016-09-30	7,281,000	shares	92
2016-01-01 to 2016-09-30	6,935,000	shares	274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-0.39	USD/shares	92
2017-01-01 to 2017-09-30	-0.91	USD/shares	273
2016-07-01 to 2016-09-30	-0.29	USD/shares	92
2016-01-01 to 2016-09-30	-0.14	USD/shares	274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-0.39	USD/shares	92
2017-01-01 to 2017-09-30	-0.91	USD/shares	273
2016-07-01 to 2016-09-30	-0.29	USD/shares	92
2016-01-01 to 2016-09-30	-0.54	USD/shares	274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	1,700,000	USD	92
2017-01-01 to 2017-09-30	2,332,915	USD	273
2016-07-01 to 2016-09-30	800,000	USD	92
2016-01-01 to 2016-09-30	1,309,109	USD	274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-4,172,574	USD	92
2017-01-01 to 2017-09-30	-8,982,701	USD	273
2016-07-01 to 2016-09-30	-2,721,637	USD	92
2016-01-01 to 2016-09-30	-6,900,949	USD	274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-09-30	7,704,265	USD
At 2016-12-31	7,921,392	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-09-30	1,768,062	USD
At 2016-12-31	1,736,805	USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	310,493	USD	273
2016-01-01 to 2016-09-30	0	USD	274

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	4,172,574	USD	92
2017-01-01 to 2017-09-30	8,982,701	USD	273
2016-07-01 to 2016-09-30	2,721,637	USD	92
2016-01-01 to 2016-09-30	6,900,949	USD	274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	1,623,302	USD	92
2017-01-01 to 2017-09-30	3,815,119	USD	273
2016-07-01 to 2016-09-30	1,109,332	USD	92
2016-01-01 to 2016-09-30	3,343,248	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-09-30	10,500,000	shares
At 2016-12-31	8,400,000	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2017-09-30	160,662,286	USD
At 2016-12-31	151,991,974	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	2,549,272	USD	92
2017-01-01 to 2017-09-30	5,167,582	USD	273
2016-07-01 to 2016-09-30	1,612,305	USD	92
2016-01-01 to 2016-09-30	3,557,701	USD	274

Inspect the source

Entity: MARKER THERAPEUTICS, INC. / CIK 0001094038
Captured: 2026-09-20T05:22:11.393Z
SEC response SHA-256: 11a45295baae8ad4450041d3d51c2454c6531734b6bbb806e124ea5eb0db02da

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001094038.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))